Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 18/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5204918 | 1.00 | ADORA2B (0.42) | ADORA2BPOLBTDP1L3MBTL1KDM4E | |
| SCHEMBL6619538 | 1.00 | ADORA2B (0.42) | ADORA2BPOLBTDP1L3MBTL1KDM4E | |
| SCHEMBL6619534 | 1.00 | ADORA2B (0.42) | ADORA2BPOLBTDP1L3MBTL1KDM4E | |
| SCHEMBL5210263 | 0.71 | KDM4E (0.43) | ADORA2BPOLBTDP1L3MBTL1KDM4E | |
| SCHEMBL5212952 | 0.68 | ADORA2B (0.37) | ADORA2BPOLBTDP1L3MBTL1KDM4E | |
| SCHEMBL7462787 | 0.68 | ALDH1A1 (0.42) | ADORA2BPOLBTDP1L3MBTL1KDM4E | |
| SCHEMBL7457049 | 0.68 | ALDH1A1 (0.42) | ADORA2BPOLBTDP1L3MBTL1KDM4E | |
| SCHEMBL7462796 | 0.68 | ALDH1A1 (0.42) | ADORA2BPOLBTDP1L3MBTL1KDM4E | |
| SCHEMBL4176942 | 0.67 | — | — | |
| SCHEMBL5212628 | 0.65 | ADORA2B (0.34) | ADORA2BPOLBTDP1L3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1423108-B1 | C-2' METHYLATED DERIVATIVES OF PACLITAXEL FOR USE AS ANTITUMOUR AGENTS | INDENA SPA (IT) | 2007-06-06 | — | — | EP | disclosed |
| US-7153884-B2 | C-2′ methylated derivatives of paclitaxel for use as antitumour agents | INDENA S.P.A. (IT) | 2006-12-26 | — | — | US | disclosed |
| US-20040242674-A1 | C-2' methylated derivatives of paclitaxel for use as antitumour agents | INDENA S.P.A. (IT) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242674-A1 | C-2' methylated derivatives of paclitaxel for use as antitumour agents | TOP2B, TOP2A, CCAR2 | ADORA2B 3277/4885POLB 375/4885TDP1 593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.